5HIB
EGFR kinase domain mutant "TMLR" with a pyrazolopyrimidine inhibitor
Summary for 5HIB
Entry DOI | 10.2210/pdb5hib/pdb |
Related | 5HIC |
Descriptor | Epidermal growth factor receptor, N-tert-butyl-5-{[(1-methyl-1H-pyrazol-5-yl)sulfonyl]amino}pyrazolo[1,5-a]pyrimidine-3-carboxamide (2 entities in total) |
Functional Keywords | protein kinase, inhibitor, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (Human) |
Cellular location | Cell membrane; Single-pass type I membrane protein. Isoform 2: Secreted: P00533 |
Total number of polymer chains | 1 |
Total formula weight | 37926.82 |
Authors | Eigenbrot, C.,Yu, C. (deposition date: 2016-01-11, release date: 2016-04-06, Last modification date: 2024-03-06) |
Primary citation | Foster, S.A.,Whalen, D.M.,Ozen, A.,Wongchenko, M.J.,Yin, J.,Yen, I.,Schaefer, G.,Mayfield, J.D.,Chmielecki, J.,Stephens, P.J.,Albacker, L.A.,Yan, Y.,Song, K.,Hatzivassiliou, G.,Eigenbrot, C.,Yu, C.,Shaw, A.S.,Manning, G.,Skelton, N.J.,Hymowitz, S.G.,Malek, S. Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. Cancer Cell, 29:477-493, 2016 Cited by PubMed: 26996308DOI: 10.1016/j.ccell.2016.02.010 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.85 Å) |
Structure validation
Download full validation report